FBRX
Tocagen Inc is a clinical-stage, cancer-selective gene therapy company focused on developing product candidates designed to activate a patient\'s immune system against cancer from within. Its pipeline product includes Toca 511 and Toca FC.
Forte Biosciences Inc (FBRX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C- (2.0) | D (1.3) | C+ (2.5) | C+ (2.6) | C (2.2) |
| 2026-11-04 | C+ (2.5) | C- (1.9) | D (1.3) | C+ (2.5) | C+ (2.7) | C (2.2) |
| 2026-10-28 | C+ (2.5) | C- (1.9) | D (1.3) | C+ (2.5) | C+ (2.7) | C (2.2) |
| 2026-10-21 | C+ (2.5) | C- (1.9) | D (1.3) | C+ (2.5) | F (0.0) | D+ (1.7) |
| 2026-10-14 | C+ (2.5) | C- (1.9) | D (1.3) | C+ (2.5) | F (0.0) | D+ (1.7) |